Results 341 to 350 of about 137,029 (384)

Measurement of Anti-TNF Biologics in Serum Samples of Pediatric Patients: Comparison of Enzyme-Linked Immunosorbent Assay (ELISA) with a Rapid and Automated Fluorescence-Based Lateral Flow Immunoassay. [PDF]

Pharmaceutics
Rossi C, Simeoli R, Angelino G, Cairoli S, Bracci F, Knafelz D, Romeo EF, Faraci S, Tarantino G, Mancini A, Vitale A, Vici CD, Manzoni SM, De Angelis P, Goffredo BM.   +14 more
europepmc   +1 more source

Long-Term Response Durability of Infliximab for Pediatric Inflammatory Bowel Disease in Japan: A Single Center Experience. [PDF]

Pediatr Gastroenterol Hepatol Nutr
Tsumura N, Kato K, Yasuda R, Yoshioka S, Takedatsu H, Mizuochi T.   +5 more
europepmc   +1 more source

Association of the HLA-DQA1*05 Allelic Gene Variants with Immunogenicity to Anti-TNF therapeutics-Important Differences Between Infliximab and Adalimumab. [PDF]

J Crohns Colitis
Ternette N, Liao H, Satsangi J.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Infliximab

Dermatologic Therapy, 2004
Infliximab is a chimeric monoclonal antibody that interferes with the actions of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Clinical trials of infliximab have demonstrated a rapid and substantial response in patents with psoriasis and psoriatic arthritis, substantiating the role of TNF-alpha in the immunopathogenesis of ...
Laura S, Winterfield, Alan, Menter
openaire   +2 more sources

Infliximab in ulcerative colitis [PDF]

Scandinavian Journal of Gastroenterology, 2006
In the past few decades treatment of ulcerative colitis has been significantly advanced both pharmacologically and surgically.
Gary R. Lichtenstein, Faten Aberra
openaire   +5 more sources

Infliximab

Expert Opinion on Pharmacotherapy, 2001
Infliximab (Remicade, Centocor, Inc.) is an intravenously administered monoclonal antibody to TNF proven effective in the treatment of moderate to severe Crohn's disease (CD). Its introduction in October 1998 was heralded by some as the most important addition to therapy for this condition in 50 years. Since then, additional indications have been added
E, Valle, M, Gross, S J, Bickston
openaire   +2 more sources

Commentary: detection of infliximab levels and anti‐infliximab antibodies [PDF]

Alimentary Pharmacology & Therapeutics, 2012
Clinicians treating inflammatory bowel disease frequently face the dilemma of loss of response to anti-TNF agents. Previous studies have demonstrated that poor clinical outcomes relate to a lack of circulating drug and the secondary development of antibodies to monoclonal antibodies including infliximab (ATI). 3 However, there is variability and a lack
Cynthia H. Seow, Remo Panaccione
openaire   +2 more sources

Infliximab

Drugs, 2005
Infliximab is a monoclonal antibody that binds to tumour necrosis factor-alpha and blocks its biological activity. It is approved for use in patients with rheumatoid arthritis, Crohn's disease and ankylosing spondylitis.black triangle In well designed, placebo-controlled trials of 12 or 24 weeks' duration in patients with active ankylosing spondylitis,
Gillian M. Keating, Dean M Robinson
openaire   +3 more sources